Optimum News

Optimum Strategic Communications Appoints Leading Healthcare Investor Anne Marieke Ezendam

Renowned fund manager and buyside analyst joins investor relations and strategic communications specialists 7 November 2018, London, UK: Optimum Strategic Communications (Optimum), the international strategic healthcare communications firm, announces the … Continue reading “Optimum Strategic Communications Appoints Leading Healthcare Investor Anne Marieke Ezendam”

Read more

By Optimum

Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product

Receives First Milestone Payment for NXP001 Cambridge, UK, 27 November 2018: ​​Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces … Continue reading “Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product”

By Optimum

Kiadis Pharma announces abstracts and presentations for the 60th American Society of Hematology (ASH) Annual Meeting

Amsterdam, The Netherlands, November 7, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces two data presentations at … Continue reading “Kiadis Pharma announces abstracts and presentations for the 60th American Society of Hematology (ASH) Annual Meeting”

By Optimum

Novo Seeds incubatee Embark Biotech enters collaboration with Novo Nordisk to discover novel therapeutics for obesity and metabolic disease

Embark was first incubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation in 2016 Embark co-founder and CEO, Casper Tind Hansen, serves as … Continue reading “Novo Seeds incubatee Embark Biotech enters collaboration with Novo Nordisk to discover novel therapeutics for obesity and metabolic disease”

By Optimum

Futura Medical Announces First Patient Enrolled in European Phase 3 study of MED2002 for the Treatment of Erectile Dysfunction

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health … Continue reading “Futura Medical Announces First Patient Enrolled in European Phase 3 study of MED2002 for the Treatment of Erectile Dysfunction”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH